SPRO — Spero Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $78.68m
- $2.35m
- $103.78m
- 37
- 98
- 88
- 87
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 18.1 | 9.33 | 18.3 | 53.5 | 104 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 81.4 | 88.4 | 106 | 99.3 | 82.3 |
Operating Profit | -63.2 | -79.1 | -88 | -45.8 | 21.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -60.9 | -78.3 | -89.8 | -46.4 | 25.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -60.9 | -78.3 | -89.8 | -46.4 | 22.8 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -60.9 | -78.3 | -89.8 | -46.4 | 22.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -60.9 | -78.8 | -89.8 | -46.4 | 22.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.35 | -3.52 | -2.91 | -0.83 | 0.52 |